Antibiotic In Vitro Data Needed In Labeling For Appropriate Use, PhRMA Says
Executive Summary
Removal of in vitro susceptibility data from anti-infective drug labeling could cause an escalation in inappropriate antibiotic use, the Pharmaceutical Research & Manufacturers of America said in comments on FDA's proposed drug labeling rule.
You may also be interested in...
Unfinished Labeling Business: Pregnancy, In Vitro Data, Containers
FDA's final labeling rule defers revisions to labeling issues such as the content and format of the Pregnancy subsection, inclusion of in vitro data and the requirements for container labels
Unfinished Labeling Business: Pregnancy, In Vitro Data, Containers
FDA's final labeling rule defers revisions to labeling issues such as the content and format of the Pregnancy subsection, inclusion of in vitro data and the requirements for container labels
Antibiotic Indications For Resistant Pathogens Could Rely On PK/PD – FDA
Companies seeking an indication for an antimicrobial agent to treat resistant pathogens could rely mostly on pharmacokinetic and pharmacodynamic studies, FDA said